BioLife Solutions Inc (BLFS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at BioLife Solutions Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 31.30 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 8.1% failed
- More than 10% revenue growth is expected for the coming year 17.9% passed
- Share count grows by less than 3% a year 4.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 17.4% failed
- Gross margin at 40% or higher and without meaningful erosion 64.6% passed
- Goodwill from acquisitions does not grow faster than revenue 51.4% passed
- Net debt below twice EBITDA 71 m net cash passed
- Operating cash flow covers the profits of the last three years 115 m passed
- Return on capital at 15% or higher, or up versus two years ago -0.3% failed
- Insiders hold at least 10% or are net buyers 2.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.5% below the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.25 | 0.25 – 0.25 | 114 | 91.9% | 1 |
| 12/31/2027 | 0.33 | 0.33 – 0.33 | 135 | 32.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.26 | – | -3 | -119.70 | – | 2 | 1 |
| 2025: Q1 | -0.01 | – | 24 | 29.90 | -1.90 | 2 | 2 |
| 2025: Q2 | -0.33 | – | 25 | 28.90 | -62.30 | 7 | 6 |
| 2025: Q3 | 0.01 | – | 28 | -8.20 | 2.20 | 6 | 3 |
| 2025: Q4 | 0.07 | -72.00 | 19 | – | 18.80 | 5 | -10 |
| 2026: Q1 | 0.02 | – | 28 | 14.90 | 4.30 | -1 | -1 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 8 | -5 | -7 | -0.54 | -4 | 3 | 8 |
| 2017 | 11 | -1 | -3 | -0.19 | 1 | 10 | 12 |
| 2018 | 20 | 4 | 3 | 0.20 | 2 | 43 | 45 |
| 2019 | 27 | -1 | -2 | -0.09 | 1 | 83 | 93 |
| 2020 | 48 | -3 | 3 | 0.10 | 7 | 205 | 235 |
| 2021 | 119 | -35 | -9 | -0.23 | -5 | 481 | 553 |
| 2022 | 76 | -6 | -140 | -3.29 | -8 | 364 | 450 |
| 2023 | 76 | -23 | -66 | -1.52 | -13 | 338 | 413 |
| 2024 | 82 | -7 | -20 | -0.44 | 8 | 349 | 399 |
| 2025 | 96 | -1 | -12 | -0.25 | 20 | 372 | 406 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
BioLife Solutions, Inc. entwickelt, fertigt und vermarktet Bioproduktionsprodukte und -dienstleistungen für die Zell- und Gentherapiebranche (CGT) in den USA, Europa, im Nahen Osten, in Afrika und international.
| Employees | 155 |
|---|---|
| Headquarters | Bothell, WA |
| Address | 3303 Monte Villa Parkway, 98021 Bothell, United States |
| Phone | 425 402 1400 |
| Website | biolifesolutions.com |
| IPO Date | 22. Nov 1989 |
| ISIN | US09062W2044 |
| Stock Split | 1:14 on 01/29/2014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Roderick de Greef | CEO & Chairman | 1960 |
| Sean Werner Ph.D. | Chief Technology Officer | 1974 |
| Aby J. Mathew Ph.D. | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | 1972 |
| Todd Berard | Chief Commercial Officer | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 17. Jul 2026 | Werner Sean | Chief Technology Officer | Other | 275 | 29.15 | 8,016 |
| 7. Jul 2026 | Wichterman Troy | Chief Financial Officer | Other | 844 | 27.79 | 23,455 |
| 7. Jul 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | Other | 516 | 27.79 | 14,340 |
| 7. Jul 2026 | Berard Todd | Chief Marketing Officer | Other | 293 | 27.79 | 8,142 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.